Victor Chong_Headshot Photo
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
18 mars 2024 07h05 HE | Clearside Biomedical, Inc.
ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...
Clearside Logo 2024.jpg
Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
12 mars 2024 16h05 HE | Clearside Biomedical, Inc.
- Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 - - Partner Programs Continue to Report Positive Clinical Data Utilizing SCS Microinjector® - - Strengthened...
Clearside Logo 2024.jpg
Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024
29 févr. 2024 07h05 HE | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
logo color s and clearside.jpg
Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering
07 févr. 2024 08h00 HE | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (“Clearside” or the “Company”) (NASDAQ: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to...
logo color s and clearside.jpg
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
14 déc. 2023 07h05 HE | Clearside Biomedical, Inc.
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
logo color s and clearside.jpg
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
13 nov. 2023 16h05 HE | Clearside Biomedical, Inc.
- New Licensing Partnership with BioCryst Pharmaceuticals Expands Clearside’s Proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor - - BioCryst Collaboration Provides $5...
logo color s and clearside.jpg
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference
08 nov. 2023 07h05 HE | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
logo color s and clearside.jpg
Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting
07 nov. 2023 16h20 HE | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
logo color s and clearside.jpg
Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting
02 nov. 2023 07h05 HE | Clearside Biomedical, Inc.
Clearside Biomedical announced that multiple oral & poster presentations will be delivered at the American Academy of Ophthalmology (AAO) 2023 Annual Mtg.
logo color s and clearside.jpg
Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD
01 nov. 2023 07h05 HE | Clearside Biomedical, Inc.
- Successful Completion of Recruitment Driven by Strong Clinical Site Participation and Investigator Support - - Topline Data Expected in Q3 2024 - ALPHARETTA, Ga., Nov. 01, 2023 ...